- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | 77 | GlobeNewswire (Europe) | Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant... ► Artikel lesen | |
| 07.05. | Neumora Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Neumora Therapeutics GAAP EPS of -$0.34 | 1 | Seeking Alpha | ||
| 07.05. | Neumora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | 127 | GlobeNewswire (Europe) | On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024... ► Artikel lesen | |
| 18.04. | Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success | 3 | Zacks | ||
| 16.04. | Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug | 2 | Zacks | ||
| 16.04. | FDA halts Neumora's schizophrenia drug trial over convulsions in rabbits | 2 | Pharmaceutical Technology | ||
| 15.04. | Preclinical Safety Signal Prompts FDA Clinical Hold on Neumora Schizophrenia Drug | 3 | MedCity News | ||
| 15.04. | Neumora's schizophrenia drug hit with clinical hold | 2 | BioPharma Dive | ||
| 15.04. | Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? | 1 | Benzinga.com | ||
| 15.04. | Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug | 1 | Investor's Business Daily | ||
| 15.04. | Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits | 1 | FierceBiotech | ||
| 15.04. | Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? | 1 | InvestorPlace | ||
| 15.04. | Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session | 4 | Benzinga.com | ||
| 15.04. | Neumora Tumbles as Early-Stage Study Put on Clinical Hold | 1 | BNN Bloomberg | ||
| 15.04. | FDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-Market | 1 | RTTNews | ||
| 15.04. | Neumora stock slides as FDA puts Phase 1 schizophrenia study on hold | 1 | Seeking Alpha | ||
| 15.04. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 9,700 | +3,52 % | Recursion Pharmaceuticals: Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry | SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,170 | 0,00 % | Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease | MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 38,310 | -3,26 % | Pre-market Movers: Tonix Pharmaceuticals, Avidity Biosciences, Beamr Imaging, Wheeler Real Estate Investment Trust, Molecular Partners | REDWOOD SHORES (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.30 A.M. ET).In the Green Avidity Biosciences, Inc. (RNA) is up over... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,620 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen | |
| ARCELLX | 53,81 | +0,11 % | The Latest Analyst Ratings For Arcellx | ||
| MUSTANG BIO | 0,871 | 0,00 % | Mustang Bio, Inc.: Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy | Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 13,390 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers | Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,530 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 39,675 | -3,49 % | Qiagen: Montag wird ein entscheidender Tag! | Wenig zu Lachen in der vergangenen Woche hatten vor allem Qiagen-Aktionäre. So ergibt sich im Vergleich zur Vorwoche ein Minus von 3,05 Prozent. Der Titel beendete fünf der fünf Tage im roten Bereich.... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,440 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) | Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,100 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| LENZ THERAPEUTICS | 18,320 | 0,00 % | LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress | SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,230 | 0,00 % | DelveInsight Business Research, LLP: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES | The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22... ► Artikel lesen | |
| COGENT BIOSCIENCES | 8,500 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) | Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,150 | 0,00 % | Arcutis Biotherapeutics, Inc. - 8-K, Current Report |
Das Unternehmen NEUMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,45 % bei einem Aktienkurs von 9,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
